To compare ZOLADEX 10.8 mg with ZOLADEX 3.6mg in Chinese pre-menopausal ER+ HER2- early breast cancer.

Trial Identifier: D8666C00004
Sponsor:AstraZeneca
NCTID:NCT03658213
Start Date:March 2020
Primary Completion Date: November 2021
Study Completion Date: November 2021
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

CountryLocation
China Beijing, China, 100006
China Chengdu, China, 610041
China Guangzhou, China, 510060
China Guangzhou, China, 510100
China Hangzhou, China, 310022
China Hangzhou, China, 310009
China Harbin, China, 150081
China Shanghai, China, 200032
China Shenyang, China, 110016
China Shijiazhuang, China, 050035
China Tianjin, China, 300060